Investigating how persistent signaling in CD4 T cells can improve cancer treatment
Persistent STAT5 signaling in polyfunctional CD4 T cells and its application in adoptive T cell therapy
This study is looking at ways to make CAR T-cell therapy work better for cancer patients by figuring out how a protein called STAT5 can help T cells become stronger and more effective at fighting tumors, especially for those who haven't had much success with current treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Augusta University NIH-funded |
| Lab location | 1 site (Augusta, United States) |
| Project ID | NIH-10891676 on NIH RePORTER |
What this research studies
This research focuses on enhancing the effectiveness of adoptive T-cell therapy, particularly for patients receiving CD19-targeting CAR T-cell therapy. It aims to understand how persistent signaling through a protein called STAT5 can help CD4 T cells become more functional and better at fighting cancer. By using advanced techniques to analyze the genetic and epigenetic changes in these T cells, the researchers hope to develop strategies that improve their ability to persist and infiltrate tumors. This could lead to better outcomes for patients who currently do not respond well to existing therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients undergoing CAR T-cell therapy, particularly those with CD19-positive cancers.
Not a fit: Patients with solid tumors that are not targeted by CD19 CAR T-cell therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments that improve patient responses and reduce relapses.
How similar studies have performed: Other research has shown promise in enhancing T-cell functionality through genetic modifications, indicating potential for success in this approach.
Where this research is happening
Augusta, United States
- Augusta University — Augusta, United States (Active)
Researchers
- Principal investigator: Zhou, Gang — Augusta University
- Study coordinator: Zhou, Gang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.